Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of the first 3,000 patients

Modern Rheumatology

Volumn 22, Issue 4, 2012, Pages 498-508

  Koike, Takao ^a   Harigai, Masayoshi ^b   Ishiguro, Naoki ^c   Inokuma, Shigeko ^d   Takei, Shuji ^e   Takeuchi, Tsutomu ^f   Yamanaka, Hisashi ^g   Tanaka, Yoshiya ^h  

^a NTT CORPORATION   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

^f KEIO UNIVERSITY   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^h UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Adalimumab; Effectiveness; Postmarketing surveillance; Rheumatoid arthritis; Safety

Indexed keywords

ADALIMUMAB; GLUCOCORTICOID; METHOTREXATE;

ADULT; AGED; APPLICATION SITE REACTION; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BIOLOGICAL THERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HERPES ZOSTER; HUMAN; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEOPLASM; PATIENT SELECTION; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEPSIS; TREATMENT RESPONSE; TUBERCULOSIS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; GLUCOCORTICOIDS; HEALTH STATUS; HUMANS; JAPAN; JOINTS; LUNG DISEASES; MALE; METHOTREXATE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865376327     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0541-5     Document Type: Article

References (30)

1. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189-94. (Pubitemid 351183307)
2. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898-906.
3. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009; 19:351-7.
4. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(Suppl 1):1-12. (Pubitemid 38269929)
5. Shiokawa Y. International conference for the bone and joint decade. Rheumatic diseases at the dawn of the millennium. J Rheumatol. 2003;30(Suppl 67):1-2.
6. Mugitani M. International conference for the bone and joint decade. Bone and joint diseases around the world. Japan: strategy for rheumatic disease control. J Rheumatol. 2003;30(Suppl 67):47. (Pubitemid 36961227)
7. Hakoda M, Oiwa H, Kasagi F, Masunari N, Yamada M, Suzuki G, Fujiwara S. Mortality of rheumatoid arthritis in Japan: a longitudinal cohort study. Ann Rheum Dis. 2005;64:1451-5. (Pubitemid 41623856)
8. Miyasaka N, CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18:252-62.
9. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17:451-8.
10. HUMIRA (adalimumab) [prescribing information]. Pharmaceuticals and medical devices agency web site. http://www.info. pmda.go.jp/downfiles/ph/PDF/ 100159-3999426G1024-1-09.pdf. Accessed 22 November 2010 (in Japanese).
11. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140:659-62.
12. International Conference on Harmonisation (ICH) Steering Committee. ICH Harmonised Tripartite Guideline. Clinical safety data management: definitions and standards for expedited reporting. Pharmaceuticals and medical devices agency web site. http://www.pmda.go.jp/ich/e/e2a-95-3-20e.pdf. Accessed 22 November 2010.
13. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford). 2004;43:1252-5. (Pubitemid 39359299)
14. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65: 889-94.
15. Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68:1863-9.
16. Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2010;6: 644-52.
17. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287-93.
18. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52: 3403-12. (Pubitemid 41612206)
19. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:2368-76. (Pubitemid 44204996)
20. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007;66:1339-44. (Pubitemid 47492478)
21. Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010;40:2-14.
22. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, British Society for Rheumatology Biologics Register, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011; 50:124-31.
23. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor (TNF) inhibitor; a report from the Registry of Japanese Rheumatoid Arthritis Patients for Long-Term Safety (REAL). J Rheumatol. 2011;38:1258-64.
24. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010;69:380-6.
25. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-300.
26. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628-34. (Pubitemid 43228641)
27. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1074-81.
28. Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford). 2010;49:82-90.
29. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21:343-51.
30. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006;54:3399-407. (Pubitemid 44737150)